The blood brain barrier (BBB) presents a formidable challenge to the delivery of drugs into
the brain. Several strategies aim to overcome this obstacle and promote efficient and …

Dysregulation of peptide-activated pathways causes a range of diseases, fostering the
discovery and clinical development of peptide drugs. Many endogenous peptides activate G …

Brain delivery is one of the major challenges in drug development because of the high
number of patients suffering from neural diseases and the low efficiency of the treatments …

Purpose: ANG1005, a novel taxane derivative, consists of three paclitaxel molecules
covalently linked to Angiopep-2, designed to cross the blood–brain and blood …

The blood–brain barrier (BBB) is a highly specialized neurovascular unit, initially described
as an intact barrier to prevent toxins, pathogens, and potentially harmful substances from …

Nearly one in six people worldwide suffer from disorders of the central nervous system
(CNS). There is an urgent need for effective strategies to improve the success rates in CNS …

This book presents 55 clinical cases emphasizing the basic science aspects of pathology
and is “the closest you can get to the wards without seeing patients.” Each case includes an …

Biologics are an emerging class of medicines with substantial promise to treat neurological
disorders such as Alzheimer's disease, stroke, and multiple sclerosis. However, the blood …

Peptide-based strategies have received an enormous amount of attention because of their
specificity and applicability. Their specificity and tumor-targeting ability are applied to …

Extravasation is the first step for nanomedicines in circulation to reach targeted solid tumors.
Traditional nanomedicines have been designed to extravasate into tumor interstitium …